Once again, the pharmaceutical companies have failed to suspend the execution of negotiations for the retrieval of insurance that has been paid for 'choline alfoscerate.' Both of the trials that were filed by two groups of pharmaceutical companies against the health authorities in Korea were dismissed by the court.

According to industry officials, the Seoul High Court 1-1 ruled to dismiss the appeal by 28 companies including
Chong Kun Dang filed to suspend the execution of negotiations on the retrieval of insurance.

After the Seoul Administrative Court rejected the claim for the suspension of execution on January 29th, Chong Kun Dang and the other companies immediately appealed